Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver
[Display omitted] •Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, bu...
Gespeichert in:
Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2017-01, Vol.132, p.165-172 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 172 |
---|---|
container_issue | |
container_start_page | 165 |
container_title | Journal of pharmaceutical and biomedical analysis |
container_volume | 132 |
creator | Liu, Xiawen Zhu, Lijun Huang, Biyun Huang, Junjun Cai, Yi Zhu, Liu Wu, Bo Fu, Xiaojing Zhang, Xingfei Rong, Yi Xiao, Qing Guo, Jiewen Li, Arong Guo, Yifei Yuan, Mu |
description | [Display omitted]
•Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF.
Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF. |
doi_str_mv | 10.1016/j.jpba.2016.09.038 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1835438785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708516307129</els_id><sourcerecordid>1835438785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</originalsourceid><addsrcrecordid>eNp9kM1q3DAUhUVJaaZpX6CLomU2diVblmTIJoT-QaBZNJCd0M81aJCtiaQZknVevDKThKy6uOgizvngfgh9oaSlhPJv23a7M7rt6t6SsSW9fIc2VIq-6Ti7O0EbInraCCKHU_Qx5y0hZKAj-4BOOyEYo2LYoKebGBPWi8Ow6KX4mCGALf4A2PioD9oHbXzw5RHHCS96KnHnnQ8v8RlSxj5jtwdcIoaHAkte2ysyF0jwhjhD0SYGn2fsF5x0waF-p0_o_aRDhs_P7xm6_fH979Wv5vrPz99Xl9eN7QdeGjtJzflER5BdnclqC5wJC6yz0nEQjhnnRq67npmRGiuZ05QaPrGBgmP9GTo_cncp3u8hFzX7bCEEvUDcZ0VlP7BeCjnUaHeM2hRzTjCpXfKzTo-KErXKV1u1ylerfEVGVeXX0tdn_t7M4F4rL7Zr4OIYgHrlwUNS2XpYLDifqiLlov8f_x_BsZp1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835438785</pqid></control><display><type>article</type><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</creator><creatorcontrib>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</creatorcontrib><description>[Display omitted]
•Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF.
Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2016.09.038</identifier><identifier>PMID: 27744175</identifier><language>eng</language><publisher>England: Elsevier B.V</publisher><subject>Animals ; Biological Availability ; Chromatography, High Pressure Liquid ; Female ; Glucuronidation ; Glucuronides - metabolism ; Infusions, Intravenous ; Intestinal absorption ; Intestines - drug effects ; Liver - drug effects ; Liver - metabolism ; Male ; Mass Spectrometry ; Microsomes, Liver - metabolism ; Naftopidil enantiomers ; Naphthalenes - metabolism ; Naphthalenes - pharmacokinetics ; Pharmacokinetics ; Piperazines - metabolism ; Piperazines - pharmacokinetics ; Prostatic Hyperplasia - drug therapy ; Quality Control ; Rats ; Rats, Sprague-Dawley ; Reproducibility of Results ; Stereoisomerism ; Tandem Mass Spectrometry ; Temperature ; UPLC–MS/MS</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2017-01, Vol.132, p.165-172</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</citedby><cites>FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpba.2016.09.038$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27744175$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Xiawen</creatorcontrib><creatorcontrib>Zhu, Lijun</creatorcontrib><creatorcontrib>Huang, Biyun</creatorcontrib><creatorcontrib>Huang, Junjun</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Zhu, Liu</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Fu, Xiaojing</creatorcontrib><creatorcontrib>Zhang, Xingfei</creatorcontrib><creatorcontrib>Rong, Yi</creatorcontrib><creatorcontrib>Xiao, Qing</creatorcontrib><creatorcontrib>Guo, Jiewen</creatorcontrib><creatorcontrib>Li, Arong</creatorcontrib><creatorcontrib>Guo, Yifei</creatorcontrib><creatorcontrib>Yuan, Mu</creatorcontrib><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>[Display omitted]
•Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF.
Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</description><subject>Animals</subject><subject>Biological Availability</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Glucuronidation</subject><subject>Glucuronides - metabolism</subject><subject>Infusions, Intravenous</subject><subject>Intestinal absorption</subject><subject>Intestines - drug effects</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Male</subject><subject>Mass Spectrometry</subject><subject>Microsomes, Liver - metabolism</subject><subject>Naftopidil enantiomers</subject><subject>Naphthalenes - metabolism</subject><subject>Naphthalenes - pharmacokinetics</subject><subject>Pharmacokinetics</subject><subject>Piperazines - metabolism</subject><subject>Piperazines - pharmacokinetics</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Quality Control</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Reproducibility of Results</subject><subject>Stereoisomerism</subject><subject>Tandem Mass Spectrometry</subject><subject>Temperature</subject><subject>UPLC–MS/MS</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1q3DAUhUVJaaZpX6CLomU2diVblmTIJoT-QaBZNJCd0M81aJCtiaQZknVevDKThKy6uOgizvngfgh9oaSlhPJv23a7M7rt6t6SsSW9fIc2VIq-6Ti7O0EbInraCCKHU_Qx5y0hZKAj-4BOOyEYo2LYoKebGBPWi8Ow6KX4mCGALf4A2PioD9oHbXzw5RHHCS96KnHnnQ8v8RlSxj5jtwdcIoaHAkte2ysyF0jwhjhD0SYGn2fsF5x0waF-p0_o_aRDhs_P7xm6_fH979Wv5vrPz99Xl9eN7QdeGjtJzflER5BdnclqC5wJC6yz0nEQjhnnRq67npmRGiuZ05QaPrGBgmP9GTo_cncp3u8hFzX7bCEEvUDcZ0VlP7BeCjnUaHeM2hRzTjCpXfKzTo-KErXKV1u1ylerfEVGVeXX0tdn_t7M4F4rL7Zr4OIYgHrlwUNS2XpYLDifqiLlov8f_x_BsZp1</recordid><startdate>20170105</startdate><enddate>20170105</enddate><creator>Liu, Xiawen</creator><creator>Zhu, Lijun</creator><creator>Huang, Biyun</creator><creator>Huang, Junjun</creator><creator>Cai, Yi</creator><creator>Zhu, Liu</creator><creator>Wu, Bo</creator><creator>Fu, Xiaojing</creator><creator>Zhang, Xingfei</creator><creator>Rong, Yi</creator><creator>Xiao, Qing</creator><creator>Guo, Jiewen</creator><creator>Li, Arong</creator><creator>Guo, Yifei</creator><creator>Yuan, Mu</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170105</creationdate><title>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</title><author>Liu, Xiawen ; Zhu, Lijun ; Huang, Biyun ; Huang, Junjun ; Cai, Yi ; Zhu, Liu ; Wu, Bo ; Fu, Xiaojing ; Zhang, Xingfei ; Rong, Yi ; Xiao, Qing ; Guo, Jiewen ; Li, Arong ; Guo, Yifei ; Yuan, Mu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-cf8a66f19e829e8fcace647ce42c8d6e7d4bdd96a234b91bc84da11b6f451ed43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>Biological Availability</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Glucuronidation</topic><topic>Glucuronides - metabolism</topic><topic>Infusions, Intravenous</topic><topic>Intestinal absorption</topic><topic>Intestines - drug effects</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Male</topic><topic>Mass Spectrometry</topic><topic>Microsomes, Liver - metabolism</topic><topic>Naftopidil enantiomers</topic><topic>Naphthalenes - metabolism</topic><topic>Naphthalenes - pharmacokinetics</topic><topic>Pharmacokinetics</topic><topic>Piperazines - metabolism</topic><topic>Piperazines - pharmacokinetics</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Quality Control</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Reproducibility of Results</topic><topic>Stereoisomerism</topic><topic>Tandem Mass Spectrometry</topic><topic>Temperature</topic><topic>UPLC–MS/MS</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Xiawen</creatorcontrib><creatorcontrib>Zhu, Lijun</creatorcontrib><creatorcontrib>Huang, Biyun</creatorcontrib><creatorcontrib>Huang, Junjun</creatorcontrib><creatorcontrib>Cai, Yi</creatorcontrib><creatorcontrib>Zhu, Liu</creatorcontrib><creatorcontrib>Wu, Bo</creatorcontrib><creatorcontrib>Fu, Xiaojing</creatorcontrib><creatorcontrib>Zhang, Xingfei</creatorcontrib><creatorcontrib>Rong, Yi</creatorcontrib><creatorcontrib>Xiao, Qing</creatorcontrib><creatorcontrib>Guo, Jiewen</creatorcontrib><creatorcontrib>Li, Arong</creatorcontrib><creatorcontrib>Guo, Yifei</creatorcontrib><creatorcontrib>Yuan, Mu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Xiawen</au><au>Zhu, Lijun</au><au>Huang, Biyun</au><au>Huang, Junjun</au><au>Cai, Yi</au><au>Zhu, Liu</au><au>Wu, Bo</au><au>Fu, Xiaojing</au><au>Zhang, Xingfei</au><au>Rong, Yi</au><au>Xiao, Qing</au><au>Guo, Jiewen</au><au>Li, Arong</au><au>Guo, Yifei</au><au>Yuan, Mu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2017-01-05</date><risdate>2017</risdate><volume>132</volume><spage>165</spage><epage>172</epage><pages>165-172</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><abstract>[Display omitted]
•Absorption is not the reason for the poor bioavailibilities of NAF enantiomers.•Extensive metabolism in the liver is the reason for the poor bioavailibilites.•Glucuronidation is the most important metabolic pathway for NAF enantiomers.•The glucuronidation of S(−)-NAF is faster, but less than that of R(+)-NAF.
Racemic naftopidil (NAF) is used to treat benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). It exhibits greater efficacy but requires higher dose than other ɑ1-adrenoceptor blockers because of its poor bioavailability. It was previously shown that bioavailability of S(−)-NAF (14.5%) was twice that of R(+)-NAF (6.8%). The present study aimed to elucidate the major factors contributing to the poor and enantioselective bioavailability of NAF. First, absorption of NAF enantiomers was examined using a perfusated intestinal model. NAF enantiomers were found to be equally and highly permeable in all segments of the intestine. Second, the metabolites formed in different parts of the intestine and in bile were investigated. Glucuronidation of NAF enantiomers was found to occur primarily in the liver. Third, a new method consisting of ultra performance liquid chromatography coupled with triple-quadruple mass spectrometry (UPLC–MS/MS) was employed to quantify and calculate the pharmacokinetic parameters of NAF enantiomers and their glucuronides after the enantiomers were intravenously injected into rats. The amounts of R(+)-NAF glucuronide (R(+)-NAF-G) and S(−)-NAF glucuronide (S(−)-NAF-G) were six-fold higher than that of R(+)-NAF, and three-fold higher than that of S(−)-NAF. Glucuronidation of S(−)-NAF was faster than that of R(+)-NAF, but the conjugated amount was half of that of R(+)-NAF. Thus, bioavailability of S(−)-NAF was twice that of R(+)-NAF. In conclusion, extensive phase II metabolism in the liver significantly contributes to the low bioavailability of NAF enantiomers. Glucuronidation is the most important metabolic pathway for NAF enantiomers. Glucuronidation of S(−)-NAF is faster but occurs to a lesser extent than that of R(+)-NAF.</abstract><cop>England</cop><pub>Elsevier B.V</pub><pmid>27744175</pmid><doi>10.1016/j.jpba.2016.09.038</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0731-7085 |
ispartof | Journal of pharmaceutical and biomedical analysis, 2017-01, Vol.132, p.165-172 |
issn | 0731-7085 1873-264X |
language | eng |
recordid | cdi_proquest_miscellaneous_1835438785 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Animals Biological Availability Chromatography, High Pressure Liquid Female Glucuronidation Glucuronides - metabolism Infusions, Intravenous Intestinal absorption Intestines - drug effects Liver - drug effects Liver - metabolism Male Mass Spectrometry Microsomes, Liver - metabolism Naftopidil enantiomers Naphthalenes - metabolism Naphthalenes - pharmacokinetics Pharmacokinetics Piperazines - metabolism Piperazines - pharmacokinetics Prostatic Hyperplasia - drug therapy Quality Control Rats Rats, Sprague-Dawley Reproducibility of Results Stereoisomerism Tandem Mass Spectrometry Temperature UPLC–MS/MS |
title | Poor and enantioselective bioavailability of naftopidil enantiomers is due to extensive and stereoselective metabolism in rat liver |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T12%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Poor%20and%20enantioselective%20bioavailability%20of%20naftopidil%20enantiomers%20is%20due%20to%20extensive%20and%20stereoselective%20metabolism%20in%20rat%20liver&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Liu,%20Xiawen&rft.date=2017-01-05&rft.volume=132&rft.spage=165&rft.epage=172&rft.pages=165-172&rft.issn=0731-7085&rft.eissn=1873-264X&rft_id=info:doi/10.1016/j.jpba.2016.09.038&rft_dat=%3Cproquest_cross%3E1835438785%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835438785&rft_id=info:pmid/27744175&rft_els_id=S0731708516307129&rfr_iscdi=true |